Arbutin Intervention Ameliorates Memory Impairment in a Rat Model of Lysolecethin Induced Demyelination: Neuroprotective and Anti-Inflammatory Effects Publisher Pubmed



Ashrafpour S^{1, 2} ; Nasrtaherabadi MJ² ; Sabourirad A² ; Hosseinzadeh S³ ; Pourabdolhossein F^{4, 5}
Source: Behavioural Brain Research Published:2024

Abstract

Cognitive impairment (CI) and memory deficit are prevalent manifestations of multiple sclerosis (MS). This study explores the therapeutic potential of arbutin on memory deficits using a rat hippocampal demyelination model induced by lysophosphatidylcholine (LPC). Demyelination was induced by bilateral injection of 1% LPC into the CA1 area of the hippocampus, and the treated group received daily arbutin injections (50 mg/kg, i.p) for two weeks. Arbutin significantly improved memory impairment 14 days post-demyelination as assessed by Morris water maze test. Histological and immunohistochemical analyses demonstrated that arbutin reduced demyelination suppressed pro-inflammatory markers (IL-1β, TNF-α) and increased anti-inflammatory cytokine IL-10. Arbutin also diminished astrocyte activation, decreased iNOS, enhanced anti-oxidative factors (Nrf2, HO-1), and exhibited neuroprotective effects by elevating myelin markers (MBP) and brain derived neurotrophic factor (BDNF). These findings propose arbutin as a potential therapeutic candidate for multiple sclerosis-associated memory deficits, warranting further clinical exploration. © 2024 Elsevier B.V.